Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atanu Bhattacharjee

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Lung India : Official Organ of Indian Chest Society|January 11, 2018
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Amit Joshi, Vijay Patil, Vanita Noronha, et al.
Ecancermedicalscience|November 7, 2017
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapyVanita Noronha, Vijay Patil, Amit Joshi, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
Journal of the Royal Society of Medicine|October 16, 2024
COVID-19-related morbidity and mortality in people with multiple long-term conditions: a systematic review and meta-analysis of over 4 million peopleShukrat O Salisu-Olatunji, Yogini V Chudasama, Navjot Kaur, et al.
Chemical Biology & Drug Design|March 30, 2011
A novel comparative genomics analysis for common drug and vaccine targets in Corynebacterium pseudotuberculosis and other CMN group of human pathogensDebmalya Barh, Neha Jain, Sandeep Tiwari, et al.
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Frontiers in Pharmacology|November 21, 2018
N-Substituted Pyrido-1,4-Oxazin-3-Ones Induce Apoptosis of Hepatocellular Carcinoma Cells by Targeting NF-κB Signaling PathwayChakrabhavi Dhananjaya Mohan, Hanumantharayappa Bharathkumar, Dukanya, et al.
Ecancermedicalscience|January 20, 2022
Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation-a phase 3 studyAmit Joshi, Vijay Maruti Patil, Vanita Noronha, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2020
Salvage surgery in head and neck cancer: Does it improve outcomes?Vijay Maruti Patil, Vanita Noronha, Shivakumar Thiagarajan, et al.
Oral Oncology|April 3, 2022
RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiationVijay Patil, Vanita Noronha, Amit Joshi, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Lung India : Official Organ of Indian Chest Society|January 11, 2018
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Amit Joshi, Vijay Patil, Vanita Noronha, et al.
Ecancermedicalscience|November 7, 2017
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapyVanita Noronha, Vijay Patil, Amit Joshi, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
Journal of the Royal Society of Medicine|October 16, 2024
COVID-19-related morbidity and mortality in people with multiple long-term conditions: a systematic review and meta-analysis of over 4 million peopleShukrat O Salisu-Olatunji, Yogini V Chudasama, Navjot Kaur, et al.
Chemical Biology & Drug Design|March 30, 2011
A novel comparative genomics analysis for common drug and vaccine targets in Corynebacterium pseudotuberculosis and other CMN group of human pathogensDebmalya Barh, Neha Jain, Sandeep Tiwari, et al.
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Frontiers in Pharmacology|November 21, 2018
N-Substituted Pyrido-1,4-Oxazin-3-Ones Induce Apoptosis of Hepatocellular Carcinoma Cells by Targeting NF-κB Signaling PathwayChakrabhavi Dhananjaya Mohan, Hanumantharayappa Bharathkumar, Dukanya, et al.
Ecancermedicalscience|January 20, 2022
Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation-a phase 3 studyAmit Joshi, Vijay Maruti Patil, Vanita Noronha, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2020
Salvage surgery in head and neck cancer: Does it improve outcomes?Vijay Maruti Patil, Vanita Noronha, Shivakumar Thiagarajan, et al.
Oral Oncology|April 3, 2022
RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiationVijay Patil, Vanita Noronha, Amit Joshi, et al.
Pageof 16